Engineered Stem Cells Secreting GLP-1 Protect Beta Cells and Improve Diabetes in Mice | Research

The takeaway

Mesenchymal stem cells engineered to secrete GLP-1 enhanced β-cell survival and improved glycemic control in diabetic mice, combining cell therapy with peptide drug delivery.

Cells that make medicine
Engineered stem cells continuously produce GLP-1 in the body, protecting insulin-producing cells while providing regenerative support

What the researchers found

GLP-1-secreting engineered MSCs enhanced β-cell survival and improved glycemic control in T1D mice, combining cell therapy regenerative potential with continuous GLP-1 peptide delivery.

Why it matters

T1D β-cell loss is the core problem. Stem cells that both regenerate and protect β-cells through GLP-1 secretion address this from two angles simultaneously.

How the study worked

Engineering of MSCs for GLP-1 secretion, transplantation into T1D mouse models, β-cell survival assessment, and glycemic control monitoring.

What this study cannot tell us

Mouse model. Long-term MSC survival and GLP-1 production in vivo uncertain. Immunogenicity of engineered MSCs not fully characterized.

How to read the evidence

Preclinical proof-of-concept combining two therapeutic modalities.

When this study was published

Published in 2025.

The bigger picture

Living cell factories that produce therapeutic peptides in vivo represent a new paradigm combining regenerative medicine with pharmacotherapy.

Questions still open

How long do engineered MSCs continue producing GLP-1 in vivo?
Could this approach reduce or eliminate the need for injectable insulin?
Would combining GLP-1-MSCs with immunomodulation prevent autoimmune destruction?

Common questions

Could stem cells produce diabetes medicine inside the body?

Yes. Engineered stem cells that continuously secrete GLP-1 protected insulin-producing cells and improved blood sugar in diabetic mice — essentially creating a living drug factory inside the body.

Could this cure type 1 diabetes?

It addresses two key problems: β-cell death and metabolic dysfunction. While not a cure, it moves toward a biological solution that could reduce or potentially eliminate the need for daily insulin injections.

Read the original research

Engineered MSCs secreting GLP-1 enhance β-cell survival and improve glycemic control in diabetic mice.

Biochemical and biophysical research communications, 795, 153105

View on PubMed ↗Publisher’s paper ↗

Citation

Huang, Zheng; Zhang, Yuyi; Tian, Jingwen; Song, Pengbo; Tong, Cailing; Qi, Zhongquan. (2026). Engineered MSCs secreting GLP-1 enhance β-cell survival and improve glycemic control in diabetic mice.. Biochemical and biophysical research communications, 795, 153105. https://doi.org/10.1016/j.bbrc.2025.153105